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I. Introduction 
The third component of complement, C3, plays an important role in the defense of 
mammalian organisms against microbial, fungal, viral, and parasitic infections. In 
addition, C3 and C3-derived peptides participate in inflammatory and immune 
regulatory reactions. The physiologic functions of C3 and of the complement system 
have been extensively reviewed [48, 67, 78, 82, 104]. This chapter deals exclusively 
with the molecular structure of the C3 gene and the control of its expression. There 
are several reasons to study these issues. First, the C3 gene provides a good model 
system in which to investigate eucaryotic gene expression. C3 is synthesized in a 
tissue-specific fashion, and its production is subject to regulation during acute 
inflammation. Second, inherited C3 deficiencies have been described in man and 
higher animals and, from studying the structure and expression of the normal and 
defective genes, the molecular basis of these deficiencies may be determined. Third, 
the biochemical properties of the C3 protein and its peptide derivatives and the 
physiologic effects of their interactions with other complement proteins, regulatory 
proteins, and cellular receptors must be understood in greater detail than is now 
possible. The analysis of C3 messenger RNA (mRNA), complementary DNA 
(cDNA), and the C3 gene will add to our comprehension of these properties. 
One of the striking characteristics of the C3 protein is its capacity to interact 
specifically with a variety of other polypeptides: (a) It is the substrate for proteolytic 
cleavage at a single site by the C3 convertases of the classical and alternative 
pathways of complement activation. (b) It is one of the constituents of the classical 
and alternative C5 convertases and of the alternative pathway C3 convertase. (c) It 
interacts with the regulatory proteins I (C3b-inactivator) and H (/~IH) that 
participate in the first specific steps of the catabolism of C3. (d) It is a ligand for 
several C3 receptor proteins on the surfaces of different cell types (see chapters by 
R.D. Schreiber [89] and by D.T. Fearon [35] in this volume). (e) It is modified by 
glycosyl transferases, a signal-peptidase, and one or several as yet unidentified 
enzymes that cleave the precursor polypeptide, proC3, at specific sites to generate 
the mature c~ and/~ subunits of C3. 
The main unresolved problem in the biochemical analysis of this protein is to 
determine the positions of the individual interactive sites with respect to its primary 
amino acid sequence and tertiary structure. The complete amino acid sequence of 
C3 is unknown, however, several groups of investigators are currently working on 
the sequence determination. 
This chapter will begin with a description of selected properties of C3 mRNA 
and the producion and identification of C3 cDNA clones. A summary of 
information about functionally important domains of the polypeptide derived from 
cDNA sequences follows, and finally we review our current knowledge of the gene 
and its expression. 
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II. Structure of the C3 Gene 
A. The Mouse C3 Gene 
1) Properties of Mouse C3 mRNA. The liver is the principal site of C3 synthesis 
in mice, man, and other mammals. Extrahepatic synthesis occurs mainly in 
macrophages and monocytes and to a lesser extent in fibroblasts, gut epithelial cells, 
and a few other cell types of the lymphoid and the reticuloendothelial systems [21, 
23, 24, 36, 94, 108, 109]. It has been reported that 1~ of total intracellular 
radiolabeled protein from primary tissue cultures of guinea pig liver cells is 
immunoprecipitable with anti-C3 sera. Also, 0.2~o of the total protein synthesized in 
a cell-free translation system primed with liver mRNA reacted with C3 antisera 
[16]. From these data it may be estimated that the abundance of C3 mRNA in 
rodent liver should be on the order of 0.2~o to 1~o. This estimation assumes an equal 
translation efficiency for all mRNA species and an efficient immunoreactivity of the 
translation products. The minimum size of C3 mRNA may be approximated from 
the length of the precursor polypeptide proC3. With a molecular weight of 170 000 
for the intracellular guinea pig pro C3 [-16] and 175 000 for the cell-free translation 
product from mouse liver mRNA, a minimum size of 5 000 nucleotides was 
estimated for mouse C3 mRNA [75]. The length of mouse C3 mRNA has been 
determined in several ways by using cloned cDNA probes; the result is a size of 5 100 
+_200 nucleotides, including a poly A tail with a mean length of 170 nucleotides 
[31]. C3 mRNAs from mouse macrophages and from rat livers were both shown to 
be of this size [74]. Based on the frequency of C3 clones in a cDNA library prepared 
from murine livers, the abundance of C3 mRNA is on the order of 0.2~o to 0.3~o, in 
accordance with the estimates derived above [31]. However, the relative abundance 
has not been measured precisely with quantitative RNA/DNA hybridization 
techniques and cloned probes. 
2) Cloning and Sequence Analysis of Mouse C3 cDNA. A library of mouse liver 
cDNA was prepared in the plasmid vector pBR322 and propagated in Escherichia 
coli by using standard technology. The resulting library represents mRNA species of 
the size class 5 000 nucleotides and longer. C3 cDNA clones were identified in this 
library by using hybrid promoted translation (hybrid selection of mRNA) [75]. The 
identity of C3 clones was confirmed by partial cDNA sequence analysis and 
comparison of the derived amino acid sequences with known protein sequence data 
from selected regions of rat, guinea pig, porcine, and human C3 [31]. The inserts 
carried by eight different cDNA clones represented partially overlapping sequences, 
beginning with the 3' end and extending over a continuous stretch of 4600 
nucleotides of the C3 mRNA. The 5' end and the adjacent approximately 350 
nucleotides of the mRNA were not represented in this library. These cDNA clones 
and the location of their insert sequences relative to the mRNA and the polypeptide 
chains are shown in Fig. 1. Sequences corresponding to a region close to the 5' end of 
the mRNA are given in Fig. 2. The sequence was later extended beyond the region 
cloned in primer extension experiments [31]. From a comparison of the derived 
amino acid sequence with the published sequences of the NH2-termini of the 
guinea-pig and human C3/~ subunits [42, 96, 98], this region appears to encode the 
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Fig. 1. (Lower) Restriction map of the cDNA inserts contained in clones pMLC3/1-8 and their location 
with respect to C3 mRNA. B, BamHI; EcoRI; H, HindIII; P, PstI. • •, cDNA inserts, where end 
circles symbolize PstI sites generated by the cloning procedure. The scale for the bottom line is in kilobase 
pairs (kb). (Upper) Position of the principal subunits and peptide fragments contained in the proC3 
molecule, with respect to the C3 mRNA. I, isoleucine residue at the NH2-terminus ofproC3 and mature 
C3/~. Dots preceding I indicate the amino-terminal extension peptide in the initial translation product. S, 
serine residue at the NH2-terminus of C3~ and C3a. (Reproduced with permission, Ref. 31) 
NH2-end of the mouse  C3fi subunit. The first few amino acid residues of  the mature 
mouse  C3/3 subunit, obtained from this comparison would be Ile-Pro-Met-Tyr-Ser 
(Fig. 2). Thus, the order of the subunits in the precursor polypeptide proC3 was 
deduced to be: NH2-//-c~-COOH, in agreement with the earlier conclusion of 
Goldberger et al. [42]. These investigators immunoprecipitated intracellular proC3 
and extracellular mature C3 from radiolabeled tissue cultures and compared the 
NH2-termini of  the precursor and of the mature subunits by radioamino acid 
sequencing to establish that the/~ subunit is located in the amino terminal portion of 
proC3. This conclusion was further supported by the identification of sequences 
encoding C3a (the anaphylatoxin peptide) and the C3e subunit at the expected 
positions in the central portion of the m R N A  [31]. The c D N A  sequences from the 5' 
terminal m R N A  region further indicated that the initial translation product from 
C3 m R N A  does not  start with the NHz-terminal  Ile-residue of the mature/~ subunit, 
but that it must contain an amino terminal extension peptide. From genomic D N A  
sequences, later results showed that the initial translation product must begin with a 
leader- or signal-peptide [-111] (see below and Fig. 6). 
The amino acid sequences of  the mouse  C3a anaphylatoxin peptide and of 
adjacent regions in the precursor proC3 molecule are given in Fig. 3. The COOH-  
terminus of the mouse  C3/3 chain has not been located precisely in this region 
because the amino acid sequence of mouse  C3 is unknown.  However,  the C O O H -  
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Fig. 2. Amino acid and corresponding nucleotide sequence of the NH2-terminus of mouse C3fl. (Top) The 
thickened portion in fragments 1 and 2 and an area preceding fragment 1 were sequenced. The sequence 
of this preceding region was determined from primer-extended cDNA. E=EcoRI; H=HindIII  
restriction sites. (Bottom) mRNA and amino acid sequence (single letter code), beginning with the NH 2- 
terminal Ile residue of the mature C3# subunit. E, H = EcoRl and HindIII sites as indicated in the top row 
terminus of human C3 was established as Pro-Ala-Ala by Tack and colleagues [96]. 
A Pro-Ala-Ala tripeptide is also found in the mouse proC3 sequence derived from 
cDNA (Fig. 3). Assuming that this tripeptide is indeed the COOH-terminus of 
mouse C3# and that the NH2-terminal residues of mouse C3a are Ser-Val-Gln, the 
precursor molecule contains an additional four arginine residues between these 
regions that are not part of the mature protein. These residues must be removed 
during the process in which the precursor matures into the two-chain molecule. 
One can further deduce from the cDNA sequence that mouse C3a is a 78 amino 
acid residue peptide of the same length as rat C3a. In contrast, human and porcine 
C3a are 77 residues long [25, 47, 49]. The sequence shows that mouse C3a shares 
72/78 residues (92~o homology) with rat C3a, and 52/77 and 50/77 residues with 
human and porcine C3a, respectively [25, 47, 49]. Furthermore, the cDNA 
sequence indicates that the cleavage of C3 by the C3 convertases occurs by 
hydrolysis of a single peptide bond. All of the amino acid residues contained in the 
C3c~-chain's cleavage site are retained either in the COOH-end of C3a or in the 
NH2-end of the C3e'-chain, confirming earlier reports [48, 96]. 
The amino acid sequence of the thioester bond region [-95] was derived from the 
cDNA sequence (Fig. 4). By comparison with published data on the protein 
sequence, this region is evidently highly conserved between mouse and human C3 
(35/41 amino acid residues identical). In particular, all ten amino acid residues 
common to the thioester regions of human C3, C4, and ~2-macroglobulin, and 
which are considered essential for the functioning of this region [ 17, 45, 95, 99], also 
occur in mouse C3. These residues are surrounded by a solid line in Fig. 4. 
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Fig. 3. Comparison of the amino acid sequences of C3a and its flanking regions. (Top) I ,  Portion of 
~agment 4 whose sequence was determined. The positions of the COOH-terminus (C) of the C3fl subunit 
and the NH2-terminus ~ )  of the C3e subunit and the C3a ~agment are shown. (Middle) Amino acid 
sequences. The mouse mRNA sequence was derived ~om cDNA sequence. Rat, human, and porcine 
amino acid sequence were taken ~om Jacobs et al. [49], Hugli [47], and Corbin and Hugli [25], 
respectively. (Bottom) Positions of the COOH-terminus (C) of C3a and the NH 2 -terminus (N) of C3e'. 
(Reproduced with permission, Re[ 31) 
Surprisingly, however, the second glutamyl residue, which is involved in formation 
of the thioester bond (residue 26 in Fig. 4), is coded as a glutamine. This finding must 
be considered in formulating mechanisms for the biosynthesis of this important 
bond [31, 38, 51]. 
The COOH-terminus of the mouse C3 protein has not yet been positioned on 
the cDNA map. One of the cDNA clones (pML C3/4, Fig. 1) contains a sequence 
that probably represents the 3'-end of the C3 mRNA. This clone contains a stretch 
of seven adenosine residues preceding the homopolymeric tail that links the insert to 
the plasmid vector and 16 nucleotides upstream a polyadenylation signal AAUAAA 
[80], which follows translational termination codons in all three reading frames. 
Thus, it was concluded that this region represents the 3'end of C3 mRNA. However, 
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Fig. 4 Comparison of the amino acid sequences encompassing the internal thioester site from murine 
(predicted from the nucleotide sequence) and human [99] C3d. (Upper)., Portion of fragment 5 whose 
sequence was determined. (Lower) Numbering of amino acid residues in the C3d fragment is from 
Thomas et al. [99]. The boxes indicate conserved amino acid residues that are identical in human C3d, 
C4d, and c~2-macrogJobulin [17, 45] (Reproduced with permission, Ref. 31) 
the possibility that this is only an internal adenosine-rich stretch in the 3'- 
nontranslated region of the mRNA and that the real 3' end of the mRNA is located 
further downstream is not excluded. The COOH-end of the protein must be coded 
by this region or by sequences located further upstream. No amino acid sequences 
are known for mouse C3; therefore, only human C3e can be used for comparison. 
The COOH-terminal amino acids of the human C3e chain have been determined to 
be (Ala, Val)-Gly-Ser [96]. However, this tripeptide sequence has one uncertainty 
and neither matches nor resembles the mouse protein sequences derived from the 
cDNA sequence preceding the stop codons in any of the three reading frames. This 
could mean that murine and human C3 have very different COOH-termini. 
Alternatively, the sequence reported for the COOH-end of the human C3c~ chain 
may not correspond to the COOH-end of the initial translation product. The 
published tripeptide sequence could represent the COOH-end of a processed 
version of C3c~ generated from the initial translation product bY removal of 
carboxyterminal amino acid residues. Carboxyterminal processing of both the 
murine and human C4e-chains has recently been reported [-20, 50] and may also 
occur for C3. 
3) Structure and Characterization of the Mouse C3 Gene. A gene library was 
constructed with liver DNA from adult mice of the inbred strain A/Jax by using the 
phage vector ~t1059. DNA was partially digested with the restriction endonuclease 
MboI, and DNA fragments of 13-23 kilo basepairs (kb) in length were recovered by 
preparative electrophoresis in agarose gels. The fragments were ligated into the 
Bam HI restriction sites of the phage vector, and phage particles were reconstituted 
by in vitro packaging with viral protein capsids. A library representing the entire A- 
mouse genome was obtained and screened by plaque hybridization with radiolab- 
eled, cloned C3 cDNA probes. Four genomic clones were isolated and characte- 
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rized. Two of them, ~.MC3/KW4 (KW4) and 2Mc3/KW7 (KW7), contained one 
entire copy of the mouse C3 gene together with approximately 1.2 kb of Y-and 7 kb 
of 3'-flanking sequences [11 l]  (Fig. 5). The gene is approximately 24 kb long, and 
the 5' and 3' ends were mapped precisely by comparative DNA sequence analysis of 
cDNA and genomic DNA. For  this purpose, cDNA extending to the 5' end of the 
mRNA was generated in primer-extension experiments by using cloned cDNA 
fragments as primers [11 iI.  In this manner, the sequence coding for the 5' end of the 
mRNA (cap) was located on the genomic DNA with a precision of + 2 nucleotides 
(position indicated by a r r o w  in Fig. 6). A 232 bp Hind III-Bam HI genomic DNA 
fragment containing the cap site was sequenced, and the hexanucleotide TATAAA 
(termed a TATA-box, underlined in Fig. 6) was found 28 nucleotides upstream from 
the cap site. This hexanucleotide is a typical sequence in RNA polymerase II 
promoter  regions of eucaryotic genes [26, 41]. The ATG translation initiation 
triplet is located 56 nucleotides downstream from the cap site. The following 72 bp 
contain coding information for a signal- or leader-peptide [13, 62] of typical amino 
acid sequence and composition [10] (Fig. 6). After the triplets coding for the 24 
amino acids of the signal-peptide, the genomic DNA encodes the NH2-terminus of 
the mature C3fl chain (Ile-Pro-Met). The signal hypothesis states that secreted 
glycoproteins are synthesized as primary translation products containing a signal- 
peptide, most often located at their NH2-end. Signal peptides are generally removed 
co-translationally by specific proteolytic cleavage [13]. C3 is a secreted glyco- 
protein, and from the gene sequence, it appears that the primary translation product 
carries a signal peptide. This signal-peptide possesses the following typical 
properties [10J : (a) its length (24 amino acids) falls into the normal range for such 
peptides, (b) it consists exclusively of uncharged amino acids, (c) its last residue is a 
kb 
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Fig. 5. a Restriction map of the C3 gene. BamHI restriction fragments are shown by open boxes (the 0.13 
kb fragment marked by an asterisk is possibly located towards the 3' side of the neighboring 0.75 kb 
fragment). O, EcoRI sites; A, HindIII sites, .~, Positions of the T-A-T-A-A-A box (5' end of the gene), and 
of the poly (A) addition site (3' end of the gene), b Restriction map of genomic DNA inserts carried by four 
different C3 clones. Vertical bars indicate BamHI restriction sites. (Reproduced with permission, Ref. 111) 
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Fig. 6. (Upper) Nucleotide sequence of the 232 bp HindIII-BamHI fragment, which contains the 5'end of 
the gene and partial sequence of the 3'-neighboring 900 bp and 2 700 bp BamHI fragments. The T-A-T-A- 
A-A hexanucleotide, the ATG translation initiation codon, and the first and last two nucleotides of the 
first intron are underlined. "~, the exact exon/intron boundaries; .[, the probable first nucleotide of the C3 
mRNA. The NH z-terminal amino acid residues, comprising the signal peptide and the first amino acids 
of the C3/~ subunit, are written above the triplet codons from which they are deduced. (Lower) Block 
structure of the first, second, and the beginning of the third exon. The heavy line in the bottom row 
represents exons. The thin inclined line symbolizes intron sequences that are absent from the mRNA and 
the cDNA. (Reproduced with permission, Ref. 111) 
glycine, and the transition dipeptide (Gly-Ile) is a preferred substrate for the signal- 
peptidases known  so far, (d) it contains a proline within its last six residues, and (e) its 
central por t ion  consists of eight hydrophobic  residues in an uninterrupted sequence. 
One addit ional observation supports  the hypothesis that  the sequence described 
above is a signal-peptide. As evident f rom the genomic D N A  sequence, it is coded by 
a separative first exon of  the gene [111] (Fig. 6). The sequences coding for the signal- 
peptides of  other genes (mouse immunoglobul in  light chains, [102] histocompati-  
bility antigens, [55, 56, 92]) are often contained in a separate first exon of  the gene. 
F r o m  these data, several general properties of the mouse C3 gene can be 
deduced. It  is 24 kb long, four to five times longer than the m R N A  coding sequences. 
Therefore, the ratio of noncoding to coding sequences is approximately 4:1. This 
number  falls into the range found for other eucaryotic genes transcribed by R N A  
polymerase II. The gene must  contain intervening sequences (introns) and 
sequences retrieved in the mature  m R N A  (exons), but  their exact numbers,  sizes, and 
locations have not  yet been determined except for the first and second exons and 
introns [111]. The p r o m o t o r  region contains the principal sequence known to be 
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conserved for many polymerase II genes, the TATA-box. The C3-TATA-box 
perfectly agrees with the consensus sequence in all six nucleotide positions [26, 41]. 
The distances from the TATA-box to the cap-site and from the cap-site to the 
translation initiation site fall into the usual range. Obviously, the promoter region 
will have to be studied in much greater detail to define other sequence elements 
relevant to the initiation of transcription by polymerase II and its regulation by 
tissue-specific and inflammatory signals. 
With regard to expression control in general and to tissue-specific expression in 
particular, it is important to know the number of C3 genes present in one (haploid) 
set of mouse chromosomes. If the genome contains a family of several C3 genes, 
tissue-specific expression could be achieved through selective expression of one 
different member in each different producer tissue. Alternatively, if only one copy is 
present per haploid genome, then the same gene must be expressed in all the 
different producer tissues. If several gene copies are present in the genome, increased 
C3 synthesis during acute inflammation could be achieved through the "switching 
on" of additional, normally silent gene copies, whereas the rate of expression from 
the constitutively expressed gene could remain constant. Alternatively, if only one 
copy of the gene is present, then increased synthesis during inflammation most likely 
would require an increased rate of expression from this single gene. To investigate 
whether the mouse genome contains one or several variants of the C3 gene, mouse 
liver DNA was digested with restriction enzymes and subjected to Southern blot 
analysis in parallel with similarly digested DNA from a mixture of the recombinant 
phages KW4 and KW7 (Fig. 7). A mixture of cloned cDNA fragments, including all 
of the C3 mRNA sequences obtained as cloned cDNA until now, plus the 232 bp 
genomic DNA fragment containing the 5' end of the gene were radiolabeled and 
used as probes. All of the Barn HI restriction fragments detected in the digest of 
genomic DNA also were found in one of the two phages (Fig. 7). Similar results were 
obtained with the restriction enzymes ECoRI and Hind III (unpublished data). 
Therefore, the mouse genome carries only one type of C3 gene recognizable by this 
analysis. If more than one copy of the C3 gene was present, then all must give rise to 
the same Barn HI, ECoRI, and Hind III restriction patterns. This analysis did not 
exclude the possibility that several copies of the C3 gene exist per haploid set of 
chromosomes, however, if several copies do exist, they must all have strictly 
conserved patterns of restriction enzyme cleavage. In view of the known rapid 
evolution of intron sequences, this is considered improbable. To the authors' 
knowledge, no gene of comparable length (24 kb) with two or more copies per 
genome and with strictly conserved cleavage patterns for three different restriction 
enzymes has been reported in the literature. Therefore, precise titration of the gene 
copy number using quantitative Southern blot or liquid hybridization experiments 
is needed and must include calibration by internal standards. From the data 
available, the mouse genome contains only one copy of the C3 gene and no 
pseudogenes, and this is the copy represented by the two recombinant phages 
2MC3/KW4 and 2MC3/KW7 [111]. 
4) C3 Allotypes and Chromosomal Location of the C3 Gene. Electrophoretic variants 
of the mouse C3 protein were first discovered by Penalva da Silva and colleagues 
[77] using high voltage electrophoresis of fresh mouse serum in agarose gels. This 
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Fig. 7. Demonstration of a single type of C3 gene by 
Southern blot analysis. Equal amounts of DNA from 
phages KW4 and KW7, see Fig. 5, were mixed and 
digested with the restriction enzyme BamHI. In parallel, 
liver DNA from strain A/Jax mice was digested with 
BamHI. The resulting fragments were separated by elec- 
trophoresis in a 0.9% agarose gel, denatured, and transfer- 
red onto nitrocellulose filters (Southern blot). The filter 
was hybridized with a mixture of nicktranslated DNA 
from cDNA plasmids, which represent 4 600 of the 5 100 
nucleotides of the C3 mRNA sequence, and with the 
nicktranslated gel eluted 232 bp HindIII-BamHI frag- 
ment from phage KW4, which contains the 5' end of the 
mouse C3 gene (see Fig. 6). Lanes a, b: 1 ng and 0,5 ng, 
respectively, of the mixture of phage DNAs KW4 and 
KW7. Lanes c, d: 15 ~tg and 10 ~tg, respectively, of mouse 
liver DNA. Fragment sizes are given in kilobases (kb) as 
determined from size markers electrophoresed in the same 
gel. The 23.1 kb mark on the left indicates traces of 
annealed phage arms containing partially digested insert 
fragments 
23.1- 
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technique had been used before [2, 4, 84] for the analysis of human C3 variants. Two 
murine variants were found, a fast migrating (F) protein and a slow one (S), similar 
to the two common forms found for human C3 [112]. Most inbred mouse strains 
were found to be homozygous for the S allele and only 4/46 strains had the 
alternative F allele. Penbred Swiss-Webster animals belonged to one of the three 
phenotypes S, F, or SF. The genes responsible for this variation were codominantly 
expressed and segregated as alleles of a single Mendelian locus. Segregation studies 
were performed after crossing S and F strains of known haplotypes in the major 
histocompatibility complex (MHC), and both the C3 and MHC markers were 
analyzed in the progeny. C3 and the MHC markers segregated together with a 
recombination frequence of 12%. The conclusion was that the C3 gene is linked to 
the MHC on mouse chromosome 17 but must be located outside the MHC, because 
the recombination distance between the MHC and C3 is 12 centimorgans (cM) 
whereas the MHC is less than 1.5 cM long. Natsuume-Sakai and coworkers [69] 
used different techniques (isoelectric focusing and immunofixation) and discovered 
two isoelectric variants of mouse C3. From the strain distribution of these variants 
and from breeding experiments, they concluded that the isoelectric variation of 
mouse C3 is inherited as an autosomal, codominant trait controlled by a single 
locus, designated C3-1. They observed linkage between C3-1 and the S region of the 
MHC and between C3-1 and the kidney catalase locus Ce-2 on chromosome 17. The 
distances reported were: C3-1/Ce-2=23cM; C3-1/S= 11 cM, in close agreement 
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with the conclusion of Penalva da Silva et al. 1-77]. The alleles controlling the 
isoelectric variants were called C3-1 a and C3-lb, but the relationship between these 
and the electrophoretic variants [77] was not established. Subsequently, the 
Japanese group raised a mouse alloantiserum directed against a determinant A 
carried by the product of the C3-la allele. With the help of this serum they detected a 
third allele, C3-1 c, at the C3-1 locus. The corresponding protein has a similar 
isoelectric point as the C3-1 a product but lacks the A determinant [70]. Later the 
same authors generated alloantisera capable of recognizing exclusively de- 
terminants B and C on the products of the C3-1 b and C3-1 ° alleles [71, 73]. 
In subsequent studies the Japanese authors used both the isoelectric focusing 
technique and these alloantisera for phenotyping C3 variants. They performed a 
three-factor-cross analysis using "tufted" (tt), a mutant'gene locus 9 cM away from 
the centromere of chromosome 17. To determine definitely the chromosomal 
location of C3-1, they phenotyped backcross progeny for the expression of tf and 
C3-1, and established that a distance of 24 cM separated these two markers [-72]. 
Since the distance between tf and the MHC was known to be about 7 cM, the 
chromosomal arrangement was concluded to be: centromere-tf-MHC-C3. 
Rubinstein et al. [86] confirmed this arrangement, using glyoxalase (glo) instead of 
tf as a third marker in a three-factor-cross. Glo was located at 17 cM on the 
centromeric side of the MHC and C3-1 on the distal side at a distance of 11 cM. 
The alloantisera were finally used to describe the molecular differences between 
the protein products of the three C3-1 alleles [-73]. After the three proteins were 
purified to homogeneity, they retained the same isoelectric and immunologic 
properties as in whole serum. Thus, the allotypic differences were attributed to 
differences in the primary structures of the corresponding gene products. By tryptic 
digestion, the allotypic determinants A and B were further located in the C3c 
fragment. All three proteins had very similar subunit sizes and compositions, 
distributions, and content of neutral sugars and sensitivity to tryptic digestion. The 
fi subunit of all three murine proteins were shorter than the human C3fl subunit by a 
molecular weight difference of 9 000. Whereas both the human c~ and B subunit are 
known to be glycosylated, only the murine C3a subunit was found to be 
glycosylated; the fl subunit was not, confirming earlier reports [37]. But, 
glycosylation differences alone could not account for the size difference between the 
murine and human fl subunit; therefore, a difference of the amino acid chain length 
is probably involved. In this context, it may be noted that Carroll and Capra [-19] 
have observed significant phylogenetic variation in the size of the C3fl subunit, but 
very little variation in the C3a subunit. 
B. The Human C3 Gene 
1) Preparation of Cloned Human C3 DNA Probes. The degree of relatedness between 
nucleotide sequences of mouse and human C3 was qualitatively evaluated in a 
Southern blot hybridization experiment (Fig. 8). The patterns of restriction enzyme 
cleavage were identical for liver DNA from two inbred mouse strains, A/Jax (s/s) 
and GR if/0, homozygous for the two major electrophoretic variants S and F of the 
mouse C3 protein [-77]. In contrast, the cleavage patterns of human peripheral 
blood cell DNA generated with three restriction enzymes differed greatly in 
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Fig. 8. Homology between murine and human C3 sequences. Murine liver DNA and human peripheral 
blood cell DNA were separately digested with three different restrictions endonucleases, EcoRI (E), 
HindIII (H), and BamHI(B). The fragments were separated by electrophoresis in agarose gels and 
subsequently transferred to a nitrocellulose filter (Southern blot). The filters were hybridized with a 
mixture of two mouse C3 cDNA plasmids carrying inserts that represent 4 600 of the 5 100 nucleotides of 
the C3 mRNA (plasmids pML C3-4 and pML C3-7 in Fig. 1). Molecular weight size markers (first and 
last track, M) are lambda phage DNA, digested with the restriction enzyme H and endlabeled with 
polynucleotide kinase and 3ZP-gamma ATP. Fragment sizes are given in kilobases (kb). Tracks 1, 2: 
DNA from A/Jax and GR-mice (C3-s/s and C3-f/f genotype, respectively [771) digested with E; Tracks 3, 
4: DNA from A/Jax and GR-mice digested with H; Tracks 5, 6: DNA from A/Jax and GR-mice digested 
with B; Tracks 7-9: Human DNA digested with E, H, and B, respectively 
f ragment  sizes f rom the co r r e spond ing  pa t te rns  of mouse  D N A .  Therefore,  sequence 
d ivers ion is clearly de tec table  between the two species. Nevertheless ,  a subs tan t ia l  
a m o u n t  of  sequence h o m o l o g y  persists because mouse  c D N A  probes  hybr id ize  
efficiently wi th  h u m a n  sequences,  and  the hybr ids  remain  stable under  condi t ions  of 
m o d e r a t e  s t r ingency [1 x SSC (s tandard  sod ium ci t ra te  buffer), 65 °C, 1 h)]. This  
obse rva t ion  suggests the usefulness of mouse  C3 c D N A  as a p robe  to isolate  h u m a n  
C3 genomic D N A  clones. In  this manner  one h u m a n  C3 genomic clone, 2HuC3 RI  
No.  5, was isola ted  f rom a gene l ib ra ry  of pa r t i a l  EcoRI  f ragments  of h u m a n  D N A  in 
a 2 rep lacement  vector  p r epa red  by Fr i t sch  and  eoworkers  [39]. This  clone 
con ta ined  a 12 kb  EcoRI  f ragment  of the  h u m a n  C3 gene and  a f lanking 5.2 kb  
fragment.  The  exon- in t ron  m a p  of the insert  has no t  been de te rmined ,  bu t  f rom 
hybr id i za t ion  with mouse  C3 c D N A  probes  represent ing  different m R N A  regions,  
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this area contains coding sequences for part of the C3e subunit (Fey, unpublished 
results). To generate a specific probe for human C3 sequences, portions of the insert 
containing nonrepetitive sequences were subcloned. For this purpose purified 12 kb 
and 5.2 kb insert fragments were digested with several restriction enzymes, and the 
fragments were analyzed by Southern blot analysis with total nick-translated DNA 
from human peripheral blood cells used as a probe. Insert fragments giving rise to a 
hybridization signal under these conditions contain repetitive sequences. In this 
experiment, a 1.39 kb Pst I subfragment of the 12 kb insert fragment was found to be 
nonrepetitive and it was subcloned [110] in the plasmid vector pxf3, a derivative of 
the standard vector pBR322 [-14] (a gift of Dr. D. Hanahan, Harvard University) 
and in M13 phage [61] (Southgate and Fey, unpublished data). Considering that 
inserts of the resulting clones, pxHu C3 pst 1.39 and M13 Hu C3 pst 1.39, hybridized 
back to e-chain coding sequences of mouse C3 cDNA, they must, at least in part, 
represent exon sequences of the human C3 gene. 
From this experiment it was also evident that almost all subfragments of the 
2Hu C3 RI No. 5 insert that are larger than 2 kb contain highly repetitive sequence 
elements. This is in agreement with the generally accepted model that human intron 
sequences are interspersed with short stretches of highly repetitive sequence 
elements (200-300 bp long) in an average distance of not more than 2 kb [29]. For 
this reason, the genomic clone 2HuC3 RI No. 5 could not be used directly for 
chromosomal mapping studies. The clones px HuC3 pst 1.39 and M13 HuC3 pst 
1.39 are at present the best unique sequence probes available for the human C3 gene. 
When DNA preparations from nucleated peripheral blood cells and tissue culture 
fibroblasts from nine unrelated human donors were tested by Southern blot 
analysis, the 12 kb ECoRI fragment was found in all these samples by usiflg the pst 
1.39 kb probe [110]. The 12 kb fragment showed no polymorphism, although the 
donors originated from different countries (Germany and England), and can 
therefore be considered a diagnostic fragment for the human C3 gene. 
2) Polymorphic Variants of the C3 Gene. Two electrophoretic variants of the C3 
protein, a slow and a fast migrating form, show inheritance patterns defining them 
as the products of two common allelic versions (C3 S and C3 F) of the gene [2, 4, 84, 
112]. In Caucasian populations these genes occur with frequencies of 0.79 and 0.20, 
respectively, whereas in Blacks C3 F is much less frequent and in at least one 
Oriental population group published, no polymorphism was detected [3]. In 
addition, until now 26 rare protein variants have been detected by one-dimensional 
electrophoresis and recognized in family studies as allelic gene products (Rittner, 
personal communication) and four rare variants by using two-dimensional 
electrophoresis (Teisberg and Olaisen, personal communication). Together the rare 
variants occur with a frequency of 0.01 in Caucasian populations. The two- 
dimensional electrophoresis showed that the two common and the four rare 
variants studied so far all had charge differences in the fi chain in accordance with 
the findings of Carroll and Capra [19]. The molecular basis of the differences in 
electrophoretic mobility of these protein variants is unexplained. More variants of 
the gene will probably be discovered on the DNA level, because even gene variants 
that differ only in intron sequences but code for identical proteins can be detected. 
Initial data are available from three independent laboratories (Davies and 
Structure and Expression of the C3 Gene 133 
colleagues, London; Roper and colleagues, Freiburg; Roses and colleagues, 
Durham, personal communication) demonstrating restriction enzyme fragment 
length polymorphisms (RFLP's) of the C3 gene that are detectable by hybridization 
with the pxHu C3 pst 1.39 probe. In family studies these gene variants were shown to 
segregate as alleles of the gene. 
3) Chromosomal Location of the Human C3 Gene. The human C3 locus has been 
assigned to chromosome 19 [110]. Somatic cell hybrids, between human primary 
fibroblasts and mouse fibroblast-like cell lines, which carried a limited number of 
different human chromosomes were analyzed for the presence of the C3 gene. Two 
approaches were used: production of human C3 in particular hybrid cultures was 
detected using a monoclonal antibody with specificity for the human but not the 
mouse gene product; and DNA samples from particular hybrid cultures were 
analyzed in Southern blot hybridization experiments using the DNA probe pxHu 
C3 pst 1.39 to detect the presence of the characteristic human C3 12 kb EcoRI 
fragment. Evidence of the presence of the human C3 gene was correlated with the 
known human chromosome content of the somatic cell hybrids. In the first 
approach, presence or absence of the human gene product correlated exclusively 
with the presence or absence of human chromosome 19 in 23 different somatic cell 
hybrids (Table 1) and in the second approach a similar exclusive correlation of the 
12 kb EcoRI fragment with chromosome 19 was observed in eight different hybrids 
(Table 2). 
The assignment of the C3 gene to chromosome 19 has allowed the assignment of 
an extensive linkage group to this chromosome. Linkage between C3 protein 
polymorphisms [3, 4, 112] and a linkage group comprising the previously linked 
Lewis blood group (LE), myotonic dystrophy (DM), ABH secretor system, and the 
Lutheran blood group (LU) loci 1-44, 63, 83] was established [32]. This extended 
linkage study confirmed the previous findings of linkage between C3 and LE [105], 
and between C3 and DM [91]. The entire C3-LE-DM-SE-LU linkage group has 
subsequently been shown to be linked with the peptidase D locus (PEPD) [33] 
which had previously and independently been assigned to chromosome 19 [59]. 
From the Southern blot hybridization experiments using pxHu C3 pst 1.39 it 
was concluded that the human haploid genome probably contains only one copy of 
the C3 gene. The pst 1.39 probe detected only one ECoRI restriction fragment, the 
12 kb fragment, in Southern blot experiments with human DNA. If the genome 
carried several copies of the C3 gene or closely related genes, then all of these should 
be located on chromosome 19 and all should give rise to an indistinguishable 12 kb 
ECoRI fragment. Multiple loci are not formally excluded by these results but were 
considered very improbable for the reasons discussed above with the mouse C3 
gene. Southern blot experiments with DNA from peripheral blood cells and sperm 
cells from the same human donor further revealed no major detectable rearrange- 
ment of the gene between its germ line and somatic cell configuration (Fig. 9). The 
C3 gene, as far as can be detected with the presently available probes, is therefore 
different from immunoglobulin genes. 
Most recently the chromosomal assignment has been further confirmed. 
Restriction fragment length polymorphisms (RFLPs) of the human C3 gene have 
been discovered in English, German, and American populations by Southern blot 
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Table 1. Segregation of expression of human C3 in 23 somatic cell hybrid subclones 
Human Expression of human C3 
chromo- 
some Concordant Discordant Total 
+ + + - - + Concordant Discordant 
1 8 1 1 4 9 5 
2 5 4 4 1 9 5 
3 6 3 3 2 9 5 
4 7 8 4 4 15 8 
5 7 3 2 2 10 4 
6 5 3 4 2 8 6 
7 8 1 1 4 9 5 
8 4 3 5 2 7 7 
9 4 3 5 2 7 7 
10 8 10 3 2 18 5 
11 8 6 3 6 14 9 
12 11 5 2 5 16 7 
13 10 1 1 11 11 12 
14" 11 5 0 6 16 6 
15 6 10 5 2 16 7 
16 7 8 "4 4 15 8 
17 9 1 0 4 10 4 
18 8 2 1 3 10 4 
19 11 12 0 0 23 0 
20* 6 9 5 2 15 7 
21 10 1 1 11 11 12 
22 5 3 4 2 8 6 
X 11 0 0 12 11 12 
+ + ,  Human C3 expressed (chromosome present); - ,  human C3 not expressed (chromosome not 
present); + - ,  human C3 expressed (chromosome not present); - + ,  human C3 not expressed 
(chromosome present). Data are summarized from karyotype and/or enzyme marker analysis of 23 
human-mouse somatic cell hybrid subclones [110] 
analysis using the pxHu C3 pst 1.39 probe. RFLPs were detected for the enzymes Sst 
I, Taq I, Bgl II [27] and Sst I, Taq I, and Hind II (Wieacker, Wienker, Grimm, 
Bender, Rogers, and Fey, unpublished data). In family studies linkage was detected 
between the C3 protein polymorphisms, C3-RFLPs and DM [27], and C3- 
RFLPs/DM and C3-RFLPs/SE as well as linkage SE/DM and DM/LE (Wieacker, 
Wienker, Grimm, Bender, Rogers, and Fey?unpublished results; and Roses, 
Pericak-Vance, Yamaoka, Carter, Stajich, Vance, Conneally, Stubblefield, and Fey, 
unpublished data). From these data it appears that the C3-RFLPs provide good 
markers for the description of the region of chromosome 19 around the DM locus. 
Finally, initial results have been obtained in experiments to determine more 
precisely the location of the C3 locus on chromosome 19. Using somatic cell hybrids 
with x/19 translocations, a map position of the C3 locus on the distal long arm of 
chromosome 19 (19 q 133-19 q ter) could be excluded (Wieacker, Fey, Voiculescu, 
and Ropers, unpublished data). By similar analyses it may be possible in the future 
to further refine the location and the orientation of this linkage group on 
chromosome 19. 
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Table 2. Segregation of hybridization of the DNA probe pxHuC3 1.39/132 to EcoRI-digested DNA from 
eight somatic cell hybrid subclones 
Human Hybridization of probe 
chromo- 
some Concordant Discordant Total 
+ + + - - +  Concordant Discordant 
1 4 0 0 4 4 4 
2 2 3 2 1 5 3 
3 2 2 2 2 4 4 
4 2 0 2 4 2 6 
5 3 2 1 2 5 3 
6 1 2 3 2 3 5 
7 4 0 0 4 4 4 
8 1 2 3 2 3 5 
9 1 2 3 2 3 5 
10 3 2 1 2 5 3 
11 2 4 2 0 6 2 
12 4 0 0 4 4 4 
13 3 0 1 4 3 5 
14 4 0 0 4 4 4 
15 2 2 2 2 4 4 
16 3 2 1 2 5 3 
17 4 0 0 4 4 4 
18 3 ! 1 3 4 4 
19 4 4 0 0 8 0 
20 3 2 1 2 5 3 
21 4 0 0 4 4 4 
22 1 2 3 2 3 5 
23 4 0 0 4 4 4 
+ +,  Probe hybridizes (chromosome present); - ,  probe does not hybridize (chromosome not present); 
+ - ,  probe hybridizes (chromosome not present); - +, probe does not hybridize (chromosome present). 
Data are summarized from karyotype and/or enzyme marker analysis of eight human-mouse somatic 
cell hybrid subclones [110] 
4) A Family Presenting Inherited Human C3 Deficiency. I n h e r i t e d  pa r t i a l  a n d  t o t a l  
C3 def ic iencies  in m a n  and  h igher  a n i m a l s  h a v e  been  desc r ibed  b u t  they  are  ra re  [6, 
113, 114]. T h e  field has  been  careful ly  r ev iewed  [3, 5] ;  the re fo re  we res t r ic t  ourse lves  
here  to  a few selected obse rva t ions .  T h e  s t a n d a r d  c o n c e n t r a t i o n  o f  C3 in h u m a n  
s e r u m  ranges  f r o m  1 to 2 mg /ml .  In  c o m p a r i s o n ,  h e t e r o z y g o u s  def ic ient  i nd iv idua l s  
h a v e  s e r u m  levels  r e d u c e d  to  ha l f  n o r m a l  values .  I f  one  a d m i t s  the  single locus  m o d e l  
of  the  C3 gene,  these  o b s e r v a t i o n s  can  be  exp la ined  by p o s t u l a t i n g  one  c o m p l e t e l y  
inac t ive  al lele  (null  allele) a n d  one  c o - d o m i n a n t l y  expressed  n o r m a l  al lele [69, 77-1. 
Pa r t i a l  def iciencies  w o u l d  imply  a pa r t i a l ly  inac t ive  gene  p r o d u c t  o r  pa r t i a l ly  
r e d u c e d  synthes is  o f  a n o r m a l  p r o d u c t  f r o m  at  least  one  defect ive  allele. Ca r r i e r s  of  
pa r t i a l  def ic iency are  genera l ly  heal thy.  O n l y  m i n o r  defects  in c o m p l e m e n t -  
m e d i a t e d  func t ions  can  be  de t ec t ed  in thei r  serum.  T h e  res idua l  C3 c o n c e n t r a t i o n  is 
a p p a r e n t l y  sufficient  to  m a i n t a i n  the  essent ia l  defense  a n d  i m m u n e  r e g u l a t o r y  
func t ions  o f  C3. 
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Fig. 9. The human C3 gene is not somati- 
cally rearranged. DNA was prepared from 
sperm cells and peripheral blood cells of 
the same human donor, and digested 
separately with one of the four different 
restriction endonucleases: PstI, HindIII, 
BamHI, and EcoRI. The fragments were 
separated by electrophosesis in an agarose 
gel and subsequently transferred to a 
nitrocellulose filter (Southern blot). The 
filter was hybridized with nicktranslated 
plasmid DNA from plasmid pxHuC3 Pst 
1.39 carrying a nonrepetitive sequence 
(probably exon-DNA) of the human C3 
gene [110]. Size markers were contained 
in the same gel, and the position of the 
diagnostic 12 kb EcoRI fragment of the 
human C3 gene is indicated. Tracks 1 to 4: 
sperm DNA digested with PstI, HindIII, 
BamHI, and EcoRI. Tracks 5 to 8: blood 
cell DNA digested with the same enzymes 
Tota l  (homozygous)  C3 deficiency in m a n  is very rare. Only  approx imate ly  half 
a dozen families of  this kind have been repor ted  [6, 8, 9, 11, 28, 43, 46, 76, 81, 85]. In  
affected individuals, the complete  absence of C3 is usually associated with such 
recurrent ,  pyogenic  infections as pneumonia ,  septicemia, otitis media,  and men-  
ingitis [-8, 9, 11, 28, 43, 46, 76, 81, 85]. Several individuals with a total  C3 def ic iency 
have died as children f rom severe infections. Replacement  of functional C3 by 
transfusion of no rma l  p lasma into deficient pat ients  transiently eliminates the 
s y m p t o m s  of these systemic infections [-76]. Sera f rom several homozygous  C3 
deficient subjects studied in vi tro showed a significant reduct ion or absence of mos t  
complemen t -med ia t ed  functions such as hemolyt ic  activity for ant ibody-sensi t ized 
sheep red b lood  cells, opsoniza t ion  of endotoxin  particles, and chemotact ic  and 
bactericidal  activities [-8, 9, 85]. Reconst i tu t ion of the deficient sera with purified 
no rma l  C3 compensa ted  for these defects. 
The  mos t  recently publ ished s tudy describes a Dutch  family [85] whose pedigree 
is reproduced in Fig. 10, with the kind permiss ion of Dr. John  Roord  and colleagues, 
Univers i ty  Hospi tals ,  Ut rech t  and Leiden, The  Netherlands.  Both  parents  are 
considered heterozygous  deficient by virtue of the reduced C3 concentra t ions  in 
their sera and the inheri tance pa t te rn  of  this deficiency in their offspring. The 
parents  are related in the seventh degree. They never exhibited serious illness and 
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Fig. 10. A family with interited C3 deficiency. Family tree of the Dutch kindred presenting three members 
with inherited total C3 deficiency, described by Roord and colleagues 1-85]. Numbers give the serum 
concentrations of immunochemically detected C3 in rag/100 ml. (With kind permission from Dr. J. 
Roord and colleagues) 
are free from clinical symptoms. Two of their 13 children died, one at the age of three 
years from bacterial meningitis and the other at the age of six years in a car accident. 
This child had no history of recurrent infections. However, three of the remaining 
children have recurring severe infections; one suffers from severaly impaired motor  
and mental development that began after the first of three episodes of meningitis. 
Other than this impairment a long-term regimen of ampicillin prophylaxis kept 
these patients well, until an attempt to discontinue the antibiotics resulted in 
renewed infections in two of the patients that necessitated resumption of continuous 
antibiotic prophylaxis. These three patients have no immunochemically detectable 
C3 antigen in their sera and only 1 -2~  of normal C3 hemolytic functional activity. 
Six of the other children are presumably heterozygous deficient; another two are 
normal. These eight are free from symptoms and have no history of recurrent 
infection. 
Until now, none of the inherited defects leading to partial or total C3 deficiency 
have been mapped to the structural locus coding for the C3 protein. Also, there are 
no well-documented reports of C3 protein mutants, although one recent publi- 
cation contains circumstantial evidence for a structural mutation of the C3 protein 
[57]. 
To further define the molecular nature of defects leading to inherited C3 
deficiencies, the first necessity is to map the site of mutation. Then one must 
distinguish between second-site mutations (affecting a control locus involved in the 
expression of the C3 gene or the biosynthesis of the C3 protein) and structural 
mutations in the coding sequences for the C3 protein. On the DNA level, such major 
alterations of the structural gene as deletions, insertions, or rearrangements are 
generally detectable by comparative Southern blot analysis with DNA from 
deficient and normal individuals. These studies have been difficult to perform in the 
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past due to the limited amounts of DNA available from the patients. To generate an 
unlimited supply of DNA from members of the Dutch family, peripheral blood B- 
lymphocytes from seven family members were transformed with EPStein-Barr Virus 
(Drs. Yvonne Boyd, D. Hunter, and J. Edwards, unpublished data; personal 
communication). Cell-lines were established in culture from one of the parents, all 
three homozygous deficient children, two that were heterozygous, and one normal 
child. These cell lines will be used for the analysis of the defect at the DNA level. 
III. Expression of the C3 Gene 
A. Tissue Specific Expression 
The C3 gene is subject to several levels of control. Most obvious is the restriction of 
its expression to production to only a few tissues. In addition, hormones and also 
inflammatory signals control the quantities of C3 circulating in the bloodstream 
and, therefore, probably the rates of synthesis in the producer tissues. 
The bulk of the circulating serum C3 is synthesized in the liver. Alper and 
colleagues convincingly demonstrated this point by assaying plasma proteins 
following orthotopic liver transplantation [7]. By taking advantage of the 
structural polymorphisms of C3, C6, C8, and factor B, they showed that more than 
90~ of the circulating forms of these proteins are synthesized in the liver. In 
addition, synthesis of C3 was demonstrated in primary hepatocyte cultures and in 
hepatoma cell lines [23, 36, 52, 64, 65, 93] (Fig. 11, tracks 3 and 4). These data 
strongly suggest that the hepatocytes are the major site of synthesis of C3. The 
percentage of hepatocytes involved in C3 synthesis under normal and inflammatory 
conditions is unknown. 
C3 is also synthesized outside of the liver. Fragments of synovial tissues 
obtained from patients with rheumatoid arthritis were capable of synthesizing 
functional C3 as well as C4 and factor B, whereas similar tissues from patients with 
degenerative or traumatic joint diseases failed to synthesize C3 in detectable 
amounts [87]. Other secondary sites of C3 synthesis include macrophages [21, 22, 
37] monocytes [34, 108], spleen cells, lymphoid cells, and other tissues of the 
reticuloendothelial systems as well as a few epithelial cell types [90, 101] and 
fibroblasts in tissue cultures [90, 109]. Gut-associated cells (hepatocytes and 
epithelial cells of the genitourinary and intestinal tracts) and cells of the 
reticuloendothelial system (macrophage/monocyte series) are the principal pro- 
ducers not only of C3 but also of most of the other complement proteins [23, 36]. 
Preliminary evidence has been presented to demonstrate the synthesis, but not 
the secretion, of several complement components by peripheral blood lymphocytes 
[94]. Peripheral blood monocytes synthesize and secrete C2, C3, C4, C5 factors B, 
D, P, I, and H as antigenically recognizable products and functionally active C2, B, 
P, D, and I. However, these cells do not secrete functionally active C3, C4, C5, C6, 
C7, or C9 in conventional tissue cultures [34, 108]. 
The molecular differences in C3 protein synthesized by monocytes that render 
this product funtionally inactive compared to C3 from hepatocytes are unknown. 
The quality in question may be a different pathway of C3 biosynthesis in these two 
tissues. Circumstantial evidence supporting this idea has been provided by a report 
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Fig. 1 I. Expression of C3 in two established 
macrophage-like and two rat hepatoma cell 
lines in tissue cultures. Culture conditions 
were as previously described for primary 
macrophages ]-37]. Cells were metabolically 
labeled by adding 50--120 gCi of 35S me- 
thionine (103 Ci/mmol) per 9 cm diameter 
dish, incubating for 1.5 h, followed by a 
chase for 1.5 h after the addition of unlabeled 
methionine to a final concentration of 300 
gM. Tissue culture supernatants were col- 
lected, centrifuged to remove floating cells, 
and brought to 10 mM in N-acetyl- 
maleimide. In the experiment shown in 
tracks 2-4, the tissue culture supernatants 
were passed three times over a gelatin- 
Sepharose column to remove fibronectin 
[ 115]. Immunoprecipitation was performed 
with commercial (Nordic, Tilburg, The 
Netherlands) rabbit anti-rat BIC (C3) se- 
rum. The immunoprecipitates were ana- 
lyzed by SDS-polyacrylamide gel electro- 
phoresis as described previously [37, 74]. 
Track 1 : direct immunoprecipitate from IC 
21 cells [58]. Tracks 2 to 4: indirect immu- 
noprecipitates from J774.2 cells [68], HTC- 
cells [100] and FaO cells [30], respectively. 
The positions of the precursor proC3 and 
the mature C3 e are indicated. The 200000 
molecular weight protein coprecipitated 
with the immunoprecipitate from HTC cells 
(arrow in Track 3) has not been identified 
of  inherited C3 deficiency. The case concerns a patient whose serum levels of C3 
were less than 1 ~  of normal  [34] ; therefore, the hepatic pa thway of product ion  
must  have been severely affected by a mutation.  However,  peripheral blood 
monocytes  taken from this patient and placed in pr imary tissue culture synthesized 
25% of normal  amounts  of a C3 molecule, with apparent ly normal  size and subunit 
composit ion.  Therefore, the monocyte  pa thway of C3 biosynthesis may not  have 
been as severely affected by the muta t ion  as that  of the liver. The appropria te  
control ,  in vitro biosynthesis of C3 by pr imary hepatocytes f rom this individual, 
could not  be performed because the cells were not  available. One direct a t tempt  was 
made to determine whether hepatocytes and macrophage /monocytes  synthesize 
different C3 molecules. However,  after analyzing the spectrum ofisoelectric variants 
of  h u m a n  C3 from monocyte  culture supernatants and from serum by immuno-  
fixation in isoelectric focusing gels, no difference was observed (Shiels and Hobar t ,  
personal  communication).  Thus, an interesting problem remains to determine why 
the h u m a n  monocy te  C3 produc t  is hemolytically inactive, exactly how it differs 
f rom the liver p roduc t  and what  its physiologic role can be. Even if monocy te  C3 
lacks hemolytic activity, it should provide an adequate  source of C3-derived peptide 
fragments, such as C3a. Therefore, one might  reasonably speculate that  an 
impor tant  role of the C3 polypeptide synthesized by peripheral cells might be to 
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serve in the amplification of localized inflammatory responses in order to confine 
peripheral centers of inflammation. Such a role for fibroblast derived C3 has 
previously been proposed [-109]. 
The C3 gene provides a useful model for the study of the molecular mechanisms 
of tissue-specific gene expression for several reasons. First, there is a clear-cut 
difference in its expression in nonproducer and producer tissues; in the main 
producer tissue, liver hepatocytes, the gene is abundantly expressed. Second, 
apparently several types of producer tissues exist (major and minor producers) with 
possible molecular differences in the C3 protein that they produce. Finally, primary 
cells from several producer tissues continue to express C3 in culture (macrophages, 
monocytes, fibroblasts, synovial cells), and established hepatoma cell lines exist that 
secrete C3. Also, specific antisera, cloned cDNA, and genomic DNA sequences are 
available as tools to monitor gene expression. Recently, this range of tools has been 
further extended by the demonstration of C3 synthesis in two permanently 
established mouse macrophage tissue culture cell-lines [743 (Fig. 11, tracks 1 and 2). 
These cell lines, IC 21 and J774.2, other than producing C3 possess several other 
characteristic properties of differentiated macrophages [58, 68]. The ultimate goal 
of comparative studies with all these cells would be to explain at the molecular level 
the mechanisms that lead to differential expression of the C3 gene in various tissues. 
B. Induction of C3 Synthesis in Acute Inflammation 
Several of the complement components are acute phase reactants in the sense that 
their serum concentrations increase during severe acute and chronic inflammation 
and after major tissue damage and surgery [53, 66]. C2, C3, C4, C5b, C9, and factor 
B have been reported to increase in concentrations during infection and tissue injury 
[ 1, 12, 97]. Concentrations of some acute phase reactants such as C-reactive protein 
(CRP) and serum amyloid A-protein (SAA) begin to rise very rapidly (within a few 
hours after injury), whereas levels of C3 and ceruloplasmin rise more slowly (within 
2-10 days). The acute phase proteins also differ markedly in the magnitude of their 
increase in concentration after stimulus. Concentrations of C3 increase about 50~o 
(from a normal value of 1.0-1.9 mg/ml to 2.2-2.6 mg/ml), whereas concentrations of 
CRP and SAA may increase several hundred-fold. C3 was reported to rise to 2.7 
mg/ml within eight days in persons with bacterial meningitis, to 2.2 mg/ml in four to 
eight days in those with acute pyelonephritis and systemic lupus erythematosus, to 
2.95 mg/ml in those with gonococcal arthritis, and to 2.2 mg/ml within one to two 
days after major surgery [54]. These values return to normal within a few days after 
disappearance of the inflammation. Because consumption of C3 usually increases as 
well, one may expect that the overall rate of synthesis may increase by more than 
50~o. It is not known whether the heightened serum concentrations result from a 
faster rate of synthesis in only those cells that were synthesizing C3 before the onset 
of inflammation, or whether additional hepatocytes and possibly other types of 
producer cells (e. g., macrophages) are recruited for synthesis. Most of the acute 
phase plasma proteins are liver products, therefore, it might be expected that the 
majority of the newly synthesized C3 appearing in serum during the acute phase 
response is made by the liver. Many acute phase products of hepatocyte origin can 
be induced by Interleukin 1 [153 and a spectrum of other agents including 
glucocorticoids, synthetic steroid hormones, thyroxin, insulin, and breakdown 
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fragments of fibrinogen [40]. However, no single major inflammatory inducer of C3 
has been identified and well-characterized except for one report of C3 regulation by 
a glucocorticoid hormone [93]. 
C. Involvement of Hormones in the Control of C3 Production 
C3 concentrations are influenced by hormones. In humans, total amounts of 
complement activity and C3 increase significantly in maternal sera late in pregnancy 
[79]. Also, Strunk and colleagues [93] reported that the biosynthesis of C3 
increased up to nine-fold after adding hydrocortisone succinate to cultured rat 
hepatoma cells, although the production of C3 and C5 in these cultures was not 
affected. This effect was observed in only one of four different C3 producing strains, 
the H4 hepatoma cell line. We have attempted to produce a similar effect with 
dexamethasone on two different established rat hepatoma cell lines, FaO [30] and 
HTC 1-100]. One of these, FaO, is a subline of the hepatoma from which the H4 line 
originated. Although both lines synthesized readily detectable amounts of C3 (Fig. 
11, tracks 3 and 4), no increase resulted. Instead, a two-fold decrease of C3 synthesis 
was observed, indicating that the published effect was specific for the particular cell 
line and possibly the particular derivative of the hormone that was used in the 
original study [-93]. 
A variety of biosynthetic and secretory functions of macrophages can be 
regulated by dexamathasone [18, 103, 106, 107]. Because we had detected C3 
synthesis in two established mouse macrophage-like cell lines [74] (Fig. 11, tracks 1 
and 2), we determined whether dexamethasone would affect the synthesis and 
secretion of C3 in the J774.2 cell line. Synthesis and secretion both diminished 
approximately two-fold in a dose dependent manner with half maximal effect 
reached at a hormone concentration of 10-7M. This effect was partially reversible 
and both intracellular proC3 and extracellular native C3 were reduced to similar 
extents. Surprisingly, the C3 mRNA concentrations were reproducibly increased 
1.5-fold under the same conditions. The mRNA concentrations were determined in 
quantitative Northern blot hybridizations by using radiolabeled, cloned cDNA 
probes for mouse C3 (Fig. 12A tracks 3 and 4). The control [staining of the same 
tracks of the gel with ethidium bromide (Fig. 12A tracks 1 and 2)] showed that 
equivalent amounts of total mRNA were contained in these tracks. The resulting 
data indicate that the hormone may affect the C3 mRNA and protein production in 
opposite ways. The hybridizations were calibrated with total mouse liver mRNA 
(Fig. 12A, tracks 5 to 7, Fig. 12B). The results show that this RNA assay is sufficiently 
sensitive to detect a two-fold change in C3 mRNA concentration. With these new 
tools, a variety of experiments can now be performed to quantitate the tissue- 
specific and inflammation controlled expression of the C3 gene into primary 
transcripts and mature mRNA. 
IV. Summary 
To map the multiple interactive sites on the C3 polypeptide, it is advantageous to 
combine the approaches of protein chemistry, nucleic acid technology, and 
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Fig. 12, Titration of C3 mRNA in hormone-treated macrophage-like cells. For calibration purposes 
mouse liver RNA was extracted and mRNA was enriched by oligo-dT cellulose chromatography as 
described previously [75]. Total cellular RNA was extracted from cells (J774.2) in tissue culture with hot 
phenol and subsequently enriched for polyadenylated mRNA [88]. RNA samples were denatured in 
glyoxal [60], electrophoresed in agarose gels, and transferred to nitrocellulose (Northern blot) as 
described previously [31]. Nicktranslated mouse C3 cDNA plasmid pMLC3-1 (Fig. 1) was used as 
hybridization probe. Panel A: Tracks 1, 2: mRNA from J 774.2 cells, before hybridization, stained with 
ethidium bromide, Tracks 3-7: autoradiographs after hybridization of the Northern blots. Tracks 1 and 
3: 9 gg ofmRNA from J774.2 cells; Tracks 2 and 4: 9 gg ofmRNA from J774.2 cells treated for 48 h with 
10-0 M dexamethasone. Tracks 5-7: decreasing amounts of mouse liver mRNA: 2.1 pg, 0.88 gg and 0.35 
i~g, respectively. Panel B: Calibration. The amounts of hybridized radioactive probe from tracks 5-7, 
Panel A were quantitated by excision of corresponding regions of the nitrocellulose filter after 
autoradiography and by counting in liquid scintillation cocktail 
molecular biology. This review summarizes the currently known molecular 
properties of  mouse liver C3 m R N A ,  cloned C3 cDNA,  and genomic DNA.  Original 
da ta  communica ted  have specified the amino acid sequence of the 215 amino- 
terminal residues of  mature  mouse C3/~. Southern blot analysis of liver D N A  
indicated that  the mouse genome contains only one type of  C3 gene, that  murine 
and human  C3 sequences strongly cross-hybridize, and that  the human  C3 gene is 
no t  somatically rearranged. Included are descriptions of  the first human  C3 
genomic D N A  clones, their preparat ion,  and their use to map  the human  C3 gene to 
ch romosome  19 in linkage with the myotonic  dys t rophy  (DM) locus. After a brief 
survey of  reports  describing inherited h u m a n  C3 deficiencies, we discuss a Du tch  
family and their three members  with total homozygous  C3 deficiency who were the 
subjects of  a recent publication. The restricted synthesis of  C3 in major  and minor  
producer  tissues is discussed and it is proposed  that  the C3 gene provides a good 
model  system for studying the molecular basis of tissue-specific gene expression. 
Da ta  are presented document ing  the product ion  of  C3 in two established mouse 
macrophage-l ike cell lines and two rat  hepa toma  cell lines in tissue cultures. A short  
account  covers the extensive literature on regulation of  C3 serum concentrat ions in 
acute and chronic inf lammation and the very incomplete picture that  presently 
depicts ho rmona l  regulation of C3 synthesis. The final experiment reported 
demonstrates  that  nucleic acid hybridizat ion with cloned c D N A  probes is a 
sensitive assay for quanti tat ive determinations of  C3 mRNA.  With  the help of  
cloned c D N A  and genomic D N A ,  researchers can address questions concerning the 
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functional topography of the C3 polypeptide, the gene's structure, and the 
molecular nature of inherited C3 deficiencies in humans. 
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Note Added in Proof 
All DNA sequences given in this manuscript have been obtained by using the Maxam-and-Gilbert 
technique. Recent extensive studies by using the M13-Dideoxy sequencing technique have revealed two 
errors in the sequence given in Fig. 2. (Lundwall, Domdey, Gibson, Tack and Fey, manuscript in 
preparation). Comparison of these sequences with those of human alpha-2-macroglobulin (Sottrup- 
Jensen, personal communication) by using the diagonal matrix computer program DIAGON (Staden 
1982, Nucleic Acids Research 10: 2951) has revealed significant (_<26~o) sequence homologies in six 
regions of the beta- and alpha-chain of mouse C3 with human alpha-2-macroglobulin. 
